PHAT
PHATHOM PHARMACEUTICALS INC
1 day chart
About PHAT
Phathom Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company, which is focused on developing and commercializing treatments for gastrointestinal (GI) diseases. The Company’s pipeline product candidate, vonoprazan is an oral small molecule potassium-competitive acid blocker (P-CAB). P-CABs are a class of medicines that block acid secretion in the stomach. Vonoprazan has an anti-secretory effect and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease (GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
Buy US stocks in Australia with $0 brokerage and trade PHAT today!
$434.06M
-
0.00%
2.79K
$11.19
$10.71
$11.19
$34.36
$6.10
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.